E-LIB Suche - Ergebnisse für: Scagnoli, F

1

211P Drug-drug interactions and their impact on clinical ou..:

Botticelli, A. ; Arpino, G. ; Bianchini, G....
ESMO Open. 9 (2024) - p. 103233 , 2024

Link: https://doi.org/10.1016/..

2

226P Prevalence and characteristics of HR+/HER2- MBC with E..:

Scafetta, R. ; Venetis, K. ; Cursano, G....
ESMO Open. 9 (2024) - p. 103248 , 2024

Link: https://doi.org/10.1016/..

3

Dynamic 3D culture promotes lymphoid tissue maturation and ..:

Barozzi, D. ; Scagnoli, F. ; Mantegazza, F....
Biomedical Science and Engineering. 4 (2023) 1 - p. , 2023

Link: https://doi.org/10.4081/..

4

70MO Genomic profiling to expand precision cancer medicine ..:

Botticelli, A. ; Scagnoli, S. ; Conte, P.F....
ESMO Open. 8 (2023) 1 - p. 100928 , 2023

Link: https://doi.org/10.1016/..

5

Pathologic response and survival after neoadjuvant chemothe..:

Fabbri A ; Nelli F ; Botticelli A...
info:eu-repo/semantics/altIdentifier/pmid/37441419. , 2023

Link: https://hdl.handle.net/1..

6

A new insight into MYC action: control of RNA polymerase II..:

Scagnoli F ; Palma A ; Favia A...
info:eu-repo/semantics/altIdentifier/pmid/36830948. , 2023

Link: https://hdl.handle.net/1..

7

Adjuvant capecitabine in triple negative breast cancer pati..:

Di Lisa F. S ; Krasniqi E ; Pizzuti L...
info:eu-repo/semantics/altIdentifier/pmid/37260975. , 2023

Link: https://hdl.handle.net/1..

8

Adjuvant capecitabine in triple negative breast cancer pati..:

Di Lisa F. S ; Krasniqi E ; Pizzuti L...
info:eu-repo/semantics/altIdentifier/pmid/37260975. , 2023

Link: https://hdl.handle.net/1..

9

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Adva..:

Botticelli A ; Fabbri A ; Roberto M...
info:eu-repo/semantics/altIdentifier/pmid/35223478. , 2022

Link: http://hdl.handle.net/11..

10

The role of immune profile in predicting outcomes in cancer..:

Botticelli A ; Pomati G ; Cirillo A...
info:eu-repo/semantics/altIdentifier/pmid/36405727. , 2022

Link: https://hdl.handle.net/1..

11

PANHER study: a 20-year treatment outcome analysis from a m..:

Pizzuti L ; Krasniqi E ; Sperduti I...
info:eu-repo/semantics/altIdentifier/pmid/35173816. , 2021

Link: http://hdl.handle.net/11..

12

Impact of baseline and on-treatment glycemia on everolimus-..:

Vernieri C ; Nichetti F ; Lalli L...
info:eu-repo/semantics/altIdentifier/pmid/33785482. , 2021

Link: http://hdl.handle.net/11..

13

Second medical opinion in oncological setting:

Maruzzo M ; La Verde N ; Russo A...
info:eu-repo/semantics/altIdentifier/pmid/33675905. , 2021

Link: http://hdl.handle.net/10..

14

Supplementary Material for: Post-Progression Treatments aft..:

Fabi A. (11802869) ; Ciccarese M. (11802872) ; Scagnoli S. (11802875)...
https://figshare.com/articles/dataset/Supplementary_Material_for_Post-Progression_Treatments_after_Palbociclib_plus_Endocrine_Therapy_in_HR_HER2_Metastatic_Breast_Cancer_Patients_What_Is_the_Better_Choice_/17134667. , 2021

Link: https://doi.org/10.6084/..

15

PANHER study: a 20-year treatment outcome analysis from a m..:

Pizzuti L ; Krasniqi E ; Sperduti I...
info:eu-repo/semantics/altIdentifier/pmid/35173816. , 2021

Link: http://hdl.handle.net/10..